SEC Form 3 · accession 0001104659-18-057858

Y-mAbs Therapeutics, Inc. · YMAB

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director · 10% Owner

Period of report

Sep 20, 2018

Accepted (ET)

Sep 20, 2018 · 6:03 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001722964

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1	holding	—	—		—	1,683,496	I	By Weco Group A/S
Common Stock^F2	holding	—	—		—	5,010,000	I	By WG Biotech ApS

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Non-Employee Stock Option (right to buy)^F3	$4.38	holding	—	—	—	—	Oct 21, 2026	Common Stock	36,000	—	D
Non-Employee Stock Option (right to buy)^F4	$11.16	holding	—	—	—	—	Apr 24, 2028	Common Stock	32,000	—	D

F1Reporting Person is the majority owner of Weco Group A/S and as such has sole voting and dispositive power with respect to such shares.
F2Reporting Person is the majority owner of WG Biotech ApS and as such has sole voting and dispositive power with respect to such shares.
F3The stock option vested and became exercisable as to 33% of the shares subject to the option on October 21, 2016, and thereafter vests as to 1/36th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the Reporting Person being a service provider on each vesting date.
F41/36th of the shares of the option to vest in equal monthly installments starting April 24, 2018 until such time as the option is 100% vested, subject to the Reporting Person continuing to be a service provider on each vesting date.